Transforming Outcomes in Hepatocellular Carcinoma: Expert Insights on Applying Evidence to Practice - Episode 1

Patients With Intermediate Stage HCC Unsuitable for TACE

February 20, 2023

Michael A. Morse, MD, Nicole Rich, MD, Pierre Gholam, MD, Daneng Li, MD, Arndt Vogel, MD

Expert panelists discuss treatment strategies for patients with intermediate stage hepatocellular carcinoma (HCC) that are unsuitable for transarterial chemoembolization (TACE).

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

Now Viewing

EP. 1: Patients With Intermediate Stage HCC Unsuitable for TACE

EP. 2: Patient Profile 1: Advanced HCC Treated with Durvalumab + Tremelimumab

EP. 3: Patients With Intermediate Stage HCC Suitable for TACE

EP. 4: HIMALAYA Study: Durvalumab + Tremelimumab in First-Line Treatment of Advanced HCC

EP. 5: Selecting the Appropriate Frontline Treatment in Advanced HCC

EP. 6: Other Frontline Immunotherapy-based Combinations in Advanced HCC

EP. 7: Patient Profile 2: Advanced HCC Treated with Lenvatinib

EP. 8: Real-World Evidence for Lenvatinib in Advanced HCC

EP. 9: Treatment Selection in Patients Unsuitable for Atezolizumab + Bevacizumab

EP. 10: Patient Profile 3: Advanced HCC Treatment in Second Line and Beyond

EP. 11: Anti-Angiogenic Systemic Therapies for Advanced HCC in Second Line and Beyond

EP. 12: Systemic Immunotherapies for Advanced HCC in Second Line and Beyond

EP. 13: Treatment Considerations for Advanced HCC in Second Line and Beyond

EP. 14: Management of Child-Pugh B Patients with Advanced HCC

EP. 15: Closing Thoughts on Advanced HCC and Highlights from ASCO GI 2023